Table 4.
Overall Adverse Events, Discontinuations, and Hematologic and Chemistry Abnormalities
| Event, n (%) | Genotype 2 or 3(N = 47) |
|---|---|
| Any adverse event | 45 (96) |
| Discontinuation of any study drug owing to an adverse event | 4 (9) |
| Serious adverse event | 4 (9) |
| Common adverse events* | |
| Influenza-like illness | 26 (55) |
| Fatigue | 15 (32) |
| Anemia | 14 (30) |
| Neutropenia | 11 (23) |
| Nausea | 8 (17) |
| Headache | 7 (15) |
| Rash | 7 (15) |
| Thrombocytopenia | 7 (15) |
| Insomnia | 6 (13) |
| Diarrhoea | 5 (11) |
| Hypertension | 5 (11) |
| Grade 3 and 4 laboratory abnormalities | |
| Decreased hemoglobin level | 13 (28) |
| Decreased lymphocyte count <499/ mm3 | 2 (4) |
| Decreased neutrophil count <750/ mm3 | 13 (28) |
| Platelet count <50,000/ mm3 | 7 (15) |
| White-cell count <1,000/ mm3 | 3 (7) |
*
Adverse events reported in at least 10% of patients in any study group.